Indian multinational pharmaceutical and healthcare products company headquartered in Delhi, operating across antibiotics, gastrointestinal, cardiovascular and dermatological medications; reported as the fourth largest pharmaceutical company by domestic sales in India as of 2023.
Clinical Trials
31
16 active
Approvals
9
Total approvals
Agencies
3
Regulatory bodies
Founded
1991
Active, not recruiting
2
6.5%
Completed
10
32.3%
Not yet recruiting
14
45.2%
Recruiting
5
16.1%
- Chandigarh University's biotechnology and pharmaceutical sciences programs placed 178 students and secured 261 industry internships over three years with companies including Sun Pharma, GSK, and Serum Institute of India. - The University Institute of Biotechnology contributed 118 placements, with MSc Biotechnology recording the highest selections at 59 students and the top salary package reaching ₹8 lakh annually. - The University Institute of Pharmaceutical Sciences achieved 60 placements, with a Pharm.D student securing the highest package of ₹9.6 LPA at Karuna Cancer Hospital. - Students have also achieved international academic success, published over 40 research papers, and founded startups including Nutripanda Life Care LLP and Nubody&CO.
- Mankind Pharma and Denovo Sciences have entered a strategic collaboration to deploy an AI-led drug discovery platform combining computational molecular generation with human expert oversight. - The partnership aims to reduce early drug discovery timelines, improve lead candidate quality, and ensure only the most viable candidates advance through development. - The collaboration employs a human-in-the-loop model where AI generates and evaluates molecular candidates while scientific experts guide and validate results at every stage. - Both companies seek to minimize time and resources spent on low-probability candidates by introducing computational precision at the earliest stage of discovery.
- Actimed Therapeutics has entered into an exclusive licensing agreement with Mankind Pharma for the development and commercialization of cancer cachexia treatments across India and South Asian territories. - The partnership focuses on S-pindolol benzoate (ACM-001.1), which Actimed plans to advance into Phase 2b/3 clinical trials for cancer cachexia treatment. - The collaboration addresses a significant unmet medical need, as cachexia affects a substantial number of cancer patients and is responsible for up to 20% of all cancer deaths, with no globally approved therapies currently available. - Mankind Pharma will assume responsibility for all development, manufacturing, and commercialization costs within the licensed territories comprising India, Bangladesh, Bhutan, Nepal, Sri Lanka, and Myanmar.
- Mankind Pharma has received approval from India's Central Drugs Standard Control Organisation (CDSCO) to initiate Phase 1 clinical trials for MKP11093, a novel JAK inhibitor targeting multiple autoimmune disorders. - The molecule is being developed to treat rheumatoid arthritis, ulcerative colitis, plaque psoriasis, and alopecia, with preclinical studies showing promising safety and selectivity profiles. - The Phase 1 trial will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers through single and multiple-ascending dose studies, representing a significant milestone in the company's drug development efforts.
- Advent International has signed a definitive agreement to invest $175 million for a significant minority stake in Felix Pharmaceuticals, a Dublin-based company developing generic medicines for companion animals. - Felix Pharmaceuticals operates in the nascent animal health generics market where generic players hold less than 10% market share, providing substantial long-term growth opportunities. - The company has achieved rapid growth since its 2015 founding, securing 14 US FDA-approved products and serving 200 clients globally through its specialized veterinary manufacturing facilities. - The global animal pharmaceutical market is projected to reach $96.56 billion by 2033, growing at a CAGR of 5.13% from 2025 to 2033, driven by increasing pet ownership and healthcare spending.
- India launches the ₹5,000 crore Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme, expected to attract ₹17,000 crore in additional R&D investment by end of 2025. - The initiative comes as 24 mega-selling drugs worth over $250 billion in combined annual sales will lose patent protection by 2030, creating unprecedented opportunities for Indian generic manufacturers. - Indian pharmaceutical companies including Zydus, Sun Pharma, and Bharat Serums are investing heavily in world-class R&D centers to develop new chemical entities and transition from generic-focused to innovation-driven operations. - The sector has grown dramatically from $8 billion in 2005-06 to $50 billion in 2023-24, with India now ranking as the world's third largest pharmaceutical producer by volume.
- Novartis has introduced a first-of-its-kind financing scheme with Pine Labs for its cholesterol-lowering drug Sybrava (inclisiran) in India, offering zero-interest EMI options to improve patient access. - The innovative payment plan allows patients to pay ₹15,000-16,000 monthly installments instead of the full ₹1.2 lakh injection cost upfront, with a one-on-one scheme providing the second injection free. - More than 3,000 patients are currently on the drug in India, with Novartis partnering with Mankind Pharma, JB Pharma, and Lupin to expand market reach through local marketing agreements. - Cardiologists remain divided on the drug's widespread use, with some viewing it as a game-changer while others suggest its application should be limited to specific patient populations.
- India's National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 84 new drug formulations, including 36 combinations containing the recently off-patent diabetes medication empagliflozin. - The price regulations follow the March 11, 2025 expiry of Boehringer Ingelheim's empagliflozin patent, opening the market to multiple pharmaceutical companies including Mankind Pharma, Lupin, and Alkem Laboratories. - Beyond diabetes medications, the NPPA's pricing decisions also cover anti-hypertensive combinations containing telmisartan and metoprolol, as well as anti-inflammatory formulations with paracetamol and mefenamic acid.
- India's CDSCO expert committee has rejected Phase III clinical trial waivers for Resmetirom tablets proposed by both Morepen Laboratories and Mankind Pharma, requiring local clinical data before marketing approval. - Resmetirom, a thyroid hormone receptor-β agonist recently approved for treating noncirrhotic NASH with moderate to advanced liver fibrosis, works by regulating lipid metabolism and reducing liver fat. - The regulatory panel has granted permission for bioequivalence studies to proceed while requesting additional clinical data, particularly from Indian and Southeast Asian populations.
- Several Indian pharmaceutical companies are preparing to launch generic versions of Empagliflozin following Boehringer Ingelheim's patent expiry on March 11, potentially transforming diabetes treatment accessibility. - Mankind Pharma plans to offer the diabetes medication at approximately Rs 6 per tablet, a 90% reduction from the innovator's price of Rs 60, with most generic versions expected to cost between Rs 9-14 per tablet. - The affordable generics will significantly reduce therapy costs for India's 10.1 crore diabetic patients, most of whom pay out-of-pocket, while still providing benefits for heart failure and chronic kidney disease management.
